Photodegradation kinetics of Bilastine in tablets

Ariele Nunes Machado; Jéssica Resch Erd; Andressa Tassinari da  Silva; Gabriela Rossi Brabo; José Luiz Ribeiro Portela; Lisiane Bajerski; Clésio Soldateli Paim

doi:10.22456/2527-2616.142956

Authors

Ariele Nunes Machado Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0009-0000-7431-1539
Jéssica Resch Erd Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0009-0004-8995-9425
Andressa Tassinari da Silva Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0009-0001-1973-1087
Gabriela Rossi Brabo Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0009-0000-0520-8693
José Luiz Ribeiro Portela Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia, Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF) - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0009-0004-4306-3041
Lisiane Bajerski Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0000-0001-7079-8036
Clésio Soldateli Paim Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade, Curso de Farmácia, Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF) - Universidade Federal do Pampa (UNIPAMPA) https://orcid.org/0000-0001-7789-0492

DOI:

https://doi.org/10.22456/2527-2616.142956

Keywords:

bilastine, photodegradation, kinetics studies

Abstract

Photodegradation is the process by which a chemical substance is broken down through exposure to light, typically ultraviolet (UV) radiation. This process is significant in environmental chemistry, where sunlight can degrade pollutants and materials, influencing their persistence and toxicity. Bilastine is a novel non-sedating histamine H1-receptor antagonist developed for the treatment of allergic rhino conjunctivitis and urticaria. The literature presents some studies on the quantitative determination of bilastine by high-performance liquid chromatography in pharmaceutical forms and biological fluids, however, no data on the photodegradation kinetics of this drug are described. Therefore, the objective of the study was to determine the photodegradation kinetics of the drug bilastine in coated tablets using a liquid chromatography method previously developed and validated by the same research group (unplished data). The study was carried out with methanolic solution containing 100.0 mg mL^-1 of bilastine drug product exposed to UV-C radiation (254 nm). The irradiation of the samples was done at pre-established times: 0, 15, 30, 60, 120 and 180 minutes. The chromatographic separation was performed in a Shim-pack^® RP-18 column; the mobile phase comprising a mixture of 0.3% triethylamine (pH adjusted to 6.0 with 20% formic acid) and acetonitrile (66:34, v/v) at a flow-rate of 1.0 mL min^-1with isocratic elution. The temperature was set at 25 °C in the column oven. Bilastine was determined by UV detection at 207 nm using photodiode-array. The results demonstrated that the photodegradation kinetics of bilastine in methanolic solution follows the first order of reaction, with a t_90% of 27.11 minutes and degradation rate constant (k) of 0.0007 min^-1.

Downloads

Download data is not yet available.

References

Lasseter KC, Sologuren A, La Noce A, Dilzer SC. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clin Drug Investig. 2013;33(9):665-673.

Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. In vivo pharmacological characterization of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D. 2006;7(4):219–231.

Sadaba B, Azanza JR, Gomez-Guiu A, Rodil R. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Ther Clin Risk Manag. 2013;9(1):197.

Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009; 39(9):1338–47.

Berrueta LA, Fernandez-Armentia M, Bakkalia A, Gonzalo A, Lucero ML, Orjales A. Matrix solid-phase dispersion technique for the determination of a q new antiallergic drug, bilastine, in rat faeces. J. Chromatogr. B. 2001; 760:185–190.

Lasseter KC, Sologuren A, La Noce A, Dilzer SC. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clin Drug Investig. 2013; 33:665-673.

Yadav AS, Prabha A, Dornala D, Swain D, Sigalapalli DK, Samanthula G. Characterization of Forced Degradation Products & Related Substances of Bilastine by Online LC-Q-TOF-MS and In-silico Study of Characterized Compounds. Anal. Chem. Lett. 2021; 11:563-579.

Terzic J, Popovic I, Stajic A, Tumpa A, JancicStojanovic B. Application of Analytical Quality by Design concept for bilastine and its degradation impurities determination by hydrophilic interaction liquid chromatographic method. J. Pharm. Biomed. Anal. 2016; 125:385–393.

Peethala P, Raja S, Palyam B, Annapurna MM. A new stability indicating RP-HPLC method for determination of Bilastine in bulk and pharmaceutical formulation. Res J Pharm Technol. 2020; 13(6):2849- 2853.

Silva AT, Brabo GR, Marques ID, Bajerski L, Malesuik MD, Paim CS. UV Spectrophotometric method for quantitative determination of Bilastine using experimental design for robustness. Drug Anal Res, 2017; 2(38-43).

Motta PR, Porto DS, Martini PRR, Bajerski L, Azeredo JB, Paula FR, Paim CS. Bilastine: Quantitative Determination by LC with Fluorescence Detection and Structural Elucidation of the Degradation Products Using HRMS. J. AOAC Int. 2020; 103(6), 1451–1460.

Martini PRR, Porto DS, Motta PR, Bajerski L, Malesuik MD, Paim, CS. Bilastine: stability-indicating a method using environmentally friendly by reversedphase high-performance liquid chromatography (RPHPLC). Drug Anal. Res., 2022; 6(1):13-20.

Ouarezki R, Guermouche S, Guermouche MH. Degradation kinetics of Bilastine determined by RPHPLC method and identification of its degradation product in oxidative condition. Chem. pap. 2020; 74:1133–1142.

Atkins P, De Paula J. editors. Physical Chemistry. 8th ed. Oxford: Oxford University Press; 2006.

Laidler KJ. Chemical Kinetics. 3rd. Bangalore: Pearson India; 2003.

Smith JM, Van Ness HC. Editors. Chemical Engineering Thermodynamics. 2nd ed. London: McGraw-Hill:1987.

Moore CB, Ravel D, Kahn, M. Free Radicals and Their Role in Photodegradation Processes. Chem Soc Rev. 1995; 24(3), 221-236.

Lang G, Wu S, Zhang, T. Kinetic Analysis of Photolytic Reactions in Aqueous Solutions. J. Phys. Chem. A. 2000; 104(5):1234-1240.

Koduru S, Tatapudi HK, Kalepuc S, Mitta C, Bairam R. Stability-indicating RP-HPLC Method Applied to the Quantification of anti-histaminic drug Ebastine in Its Oral Suspension Dosage Form. Drug Analytical Research. 2022; 6(2):8-17.

Ioele G, Grande F, De Luca M, Occhiuzzi MA, Garofalo A, Ragno G. Photodegradation of AntiInflammatory Drugs: Stability Tests and Lipid Nanocarriers for Their Photoprotection. Molecules. 2021; 26(19): 5989-6001.

Breier AR, Nudelman NS, Steppe M, Schapoval EES. Photodegradation kinetics of fexofenadine hydrochloride using an LC method. Chromatographia. 2006; 64:725–729.

Garcia CV, Nudelman NS, Steppe M, Schapoval EES. Structural elucidation of rabeprazole sodium photodegradation products. J. Pharm. Biomed. Anal. 2008; 46: 88–93.

Breier AR, Nudelman NS, Steppe M, Schapoval EES. Isolation and structure elucidation of photodegradation products of fexofenadine. J. Pharm. Biomed. Anal. 2008; 46:250–257.

International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Photostability testing of new drug substances and products – Q1B. Geneva; 1996.

International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Stability testing of new drug substances and products – Q1A(R2). Geneva; 2003.